Autumn Burnette, MD, hosts a new monthly allergy and immunology podcast from HCPLive, opening with an episode on hereditary angioedema.
News|Articles|November 9, 2026
ACAAI 2026 Preview: Late-Breakers to Watch Out For
Author(s)Chelsie Derman
Fact checked by: Victoria Johnson
Clinicians at ACAAI 2026 will see late-breaking HAE, anaphylaxis, urticaria, and food allergy data, plus exclusive expert interviews.
Advertisement
Advertisement
The American College of Allergy, Asthma & Immunology (ACAAI) 2026 Annual Scientific Meeting will convene in Phoenix, Arizona, from Thursday, November 12, to Monday, November 16, bringing together
Related to this article
Jasmohan Bajaj, MD, MS, joins Nancy Reau, MD, and Kimberly Brown, MD, on who to screen for HE in clinic and how to prepare patients and families.
Gerard Criner, MD, reviews GOLD 2026 sessions on mucus plugs and inhaler technique, plus multimorbidity, exacerbation risk, and the 2027 GOLD Report.
Dupilumab cut new or worsening allergies by 34% vs placebo in a 12-trial atopic dermatitis meta-analysis, suggesting it may slow the atopic march.
Lp(a)HORIZON and ZEUS hit their biomarker targets but not MACE. Stephen Greene, MD, and Muthiah Vaduganathan, MD, MPH, unpack both at AHA 2026.
Emma Guttman-Yassky, MD, discusses biomarker data showing rezpegaldesleukin's regulatory T-cell mechanism separates from placebo early.
Risankizumab improved skin clearance, itch, and quality of life through 52 weeks in pediatric psoriasis in the phase 3 OptIMMize-1 study.
In 3-year BE HEARD data, close to half of bimekizumab-treated HS patients reported no quality-of-life impact, regardless of baseline draining tunnel count.
Advertisement
Advertisement